Autopsy report · NCT01397591
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
Cause of deathSlow enrollment, also staffing, sites or logistics
“Study closed by PI due to lower than expected accrual.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 9 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- OHSU Knight Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
- Interventions
- Ofatumumab; Bortezomib
- Participants
- 3
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
“Study was closed to low accrual.” - Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
“Study closure based on decision of the PI” - High Dose Rate Brachyablation of Primary Liver Lesions
“Study was closed due to poor accrual” - Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients
“Study closed with no subjects accrued. PI decided to stop study.” - Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
“PI retired, study closed”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.